Literature DB >> 20182781

Cyclosporine A at reperfusion reduces infarct size in pigs.

Andreas Skyschally1, Rainer Schulz, Gerd Heusch.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20182781      PMCID: PMC2855028          DOI: 10.1007/s10557-010-6219-y

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


× No keyword cloud information.
Timely reperfusion is mandatory for salvage of ischemic myocardium from irreversible damage. However, reperfusion induces damage per se, i.e. reperfusion injury contributes to final infarct size [1]. Ischemic postconditioning, i.e. brief episodes of intermittent coronary re-occlusion during early reperfusion, reduces infarct size. This protective effect was confirmed in all species tested so far [2], including humans [3], but common co-morbidities of ischemic heart disease may interfere with cardioprotective mechanisms including ischemic postconditioning [4]. The signal transduction of ischemic postconditioning is still unclear in detail [5]. Activation of “reperfusion injury salvage kinases” (RISK) is causal for ischemic postconditioning’s protection in rodents [6]. In pigs, in which coronary anatomy and the spatial and temporal development of myocardial infarction are closer to that of humans, RISK activation is not mandatory for protection [7]. The mitochondrial permeability transition pore (mPTP) is a potential end-effector of myocardial protection at reperfusion [8-10]. Cyclosporine A binds to cyclophilin D, inhibits mPTP opening and reduces infarct size [9, 11]. Apart from experiments in rodents, cyclosporine A when given at reperfusion reduced infarct size in a proof-of-concept study in patients with acute myocardial infarction [12]. Protection by cyclosporine A at reperfusion was now tested in pigs. Enflurane-anesthetized Göttinger minipigs (20–40 kg body weight) of either sex were subjected to 90 min controlled hypoperfusion of the left anterior descending coronary artery and 120 min reperfusion [7]. In four pigs cyclosporine A (5 mg/kg i.v.) was infused 5 min before reperfusion; in four pigs, ischemic postconditioning was induced with six cycles of 20 s re-occlusion/reperfusion each; four pigs with immediate full reperfusion served as controls. Systemic hemodynamics (Table 1) and subendocardial blood flow during ischemia (microspheres) were matched between groups (Fig. 1). Both, cyclosporine A at reperfusion and ischemic postconditioning reduced infarct size (TTC staining) to a similar extent compared to controls (Fig. 1).
Table 1

Systemic hemodynamics

HR [1/min]LVPmax [mmHg]dPdtmax [mmHg/s]CAPmean [mmHg]CBFmean [ml/min]
Cyclosporine ABaseline99 ± 794 ± 71330 ± 68112 ± 522.5 ± 2.8
Isch5100 ± 679 ± 3959 ± 5520 ± 3*1.9 ± 0.1*
Isch8597 ± 577 ± 6*925 ± 4520 ± 2*1.9 ± 0.1*
Rep1091 ± 468 ± 7*796 ± 108102 ± 466.1 ± 8.9*
Rep30108 ± 772 ± 8*1060 ± 203105 ± 161.4 ± 10.9*
Rep60115 ± 770 ± 6*946 ± 117105 ± 354.8 ± 7.2*
Rep120119 ± 1065 ± 7*946 ± 111103 ± 554.1 ± 7.7*
PostconditioningBaseline100 ± 996 ± 31446 ± 36122 ± 624.6 ± 3.1
Isch5112 ± 1177 ± 7*997 ± 5922 ± 2*2.9 ± 0.6*
Isch85105 ± 977 ± 3*1112 ± 4624 ± 2*2.9 ± 0.6*
Rep10109 ± 876 ± 5*1383 ± 103109 ± 674.2 ± 9.3*
Rep30113 ± 876 ± 3*1377 ± 79111 ± 466.1 ± 8.0*
Rep60113 ± 1169 ± 12*1380 ± 416122 ± 4# 65.8 ± 10.9*
Rep120125 ± 1269 ± 5*1364 ± 259115 ± 759.1 ± 14.7*
Immediate full reperfusionBaseline93 ± 6103 ± 21294 ± 52122 ± 524.3 ± 2.6
Isch598 ± 1082 ± 2*1039 ± 8723 ± 2*2.8 ± 0.4*
Isch8594 ± 785 ± 4*1178 ± 4523 ± 1*2.8 ± 0.4*
Rep1095 ± 776 ± 5*1101 ± 173111 ± 757.6 ± 9.0*
Rep30103 ± 1272 ± 6*1278 ± 183106 ± 4*53.5 ± 7.9*
Rep60118 ± 1673 ± 2*1432 ± 111110 ± 155.1 ± 9.4*
Rep120116 ± 1561 ± 3*1222 ± 174118 ± 9# 67.1 ± 16.8*

Isch5/85: 5/85 min ischemia; Rep10/30/60/120: 10/30/60/120 min reperfusion; HR: heart rate; LVPmax: maximal left ventricular pressure; dPdtmax: maximum in the first derivative of LVP; CAPmean: mean coronary arterial pressure; CBFmean: mean coronary blood flow; means ± SEM; *p < 0.05 vs. Baseline; # p < 0.05 vs. Cyclosporine A; two-way-ANOVA with Fisher’s LSD post-hoc tests.

Fig. 1

Infarct size with cyclosporine A given at reperfusion, postconditioning, and immediate full reperfusion;means ± SEM; AAR: area at risk; ANOVA with Fisher’s LSD post-hoc tests

Systemic hemodynamics Isch5/85: 5/85 min ischemia; Rep10/30/60/120: 10/30/60/120 min reperfusion; HR: heart rate; LVPmax: maximal left ventricular pressure; dPdtmax: maximum in the first derivative of LVP; CAPmean: mean coronary arterial pressure; CBFmean: mean coronary blood flow; means ± SEM; *p < 0.05 vs. Baseline; # p < 0.05 vs. Cyclosporine A; two-way-ANOVA with Fisher’s LSD post-hoc tests. Infarct size with cyclosporine A given at reperfusion, postconditioning, and immediate full reperfusion;means ± SEM; AAR: area at risk; ANOVA with Fisher’s LSD post-hoc tests Whereas pigs differ from rodents with respect to the causal role of RISK in ischemic postconditioning, they share with both rodents and importantly also humans protection by cyclosporine A at reperfusion, suggesting an important role for mitochondrial permeability transition pore opening across all species.
  12 in total

1.  Postconditioning: old wine in a new bottle?

Authors:  Gerd Heusch
Journal:  J Am Coll Cardiol       Date:  2004-09-01       Impact factor: 24.094

2.  Cardioprotection: nitric oxide, protein kinases, and mitochondria.

Authors:  Gerd Heusch; Kerstin Boengler; Rainer Schulz
Journal:  Circulation       Date:  2008-11-04       Impact factor: 29.690

3.  Inhibition of mitochondrial permeability transition pore opening: the Holy Grail of cardioprotection.

Authors:  Gerd Heusch; Kerstin Boengler; Rainer Schulz
Journal:  Basic Res Cardiol       Date:  2010-03       Impact factor: 17.165

4.  Specific inhibition of the mitochondrial permeability transition prevents lethal reperfusion injury.

Authors:  Laurent Argaud; Odile Gateau-Roesch; Danina Muntean; Lara Chalabreysse; Joseph Loufouat; Dominique Robert; Michel Ovize
Journal:  J Mol Cell Cardiol       Date:  2005-01-26       Impact factor: 5.000

5.  Postconditioning inhibits mitochondrial permeability transition.

Authors:  Laurent Argaud; Odile Gateau-Roesch; Olivier Raisky; Joseph Loufouat; Dominique Robert; Michel Ovize
Journal:  Circulation       Date:  2005-01-10       Impact factor: 29.690

6.  Effect of cyclosporine on reperfusion injury in acute myocardial infarction.

Authors:  Christophe Piot; Pierre Croisille; Patrick Staat; Hélène Thibault; Gilles Rioufol; Nathan Mewton; Rachid Elbelghiti; Thien Tri Cung; Eric Bonnefoy; Denis Angoulvant; Christophe Macia; Franck Raczka; Catherine Sportouch; Gerald Gahide; Gérard Finet; Xavier André-Fouët; Didier Revel; Gilbert Kirkorian; Jean-Pierre Monassier; Geneviève Derumeaux; Michel Ovize
Journal:  N Engl J Med       Date:  2008-07-31       Impact factor: 91.245

7.  Ischemic postconditioning in pigs: no causal role for RISK activation.

Authors:  Andreas Skyschally; Patrick van Caster; Kerstin Boengler; Petra Gres; Judith Musiolik; Dustin Schilawa; Rainer Schulz; Gerd Heusch
Journal:  Circ Res       Date:  2008-11-26       Impact factor: 17.367

8.  Preconditioning and postconditioning: the essential role of the mitochondrial permeability transition pore.

Authors:  Shiang Y Lim; Sean M Davidson; Derek J Hausenloy; Derek M Yellon
Journal:  Cardiovasc Res       Date:  2007-05-04       Impact factor: 10.787

Review 9.  Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning.

Authors:  Peter Ferdinandy; Rainer Schulz; Gary F Baxter
Journal:  Pharmacol Rev       Date:  2007-11-29       Impact factor: 25.468

Review 10.  Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection.

Authors:  Derek J Hausenloy; Derek M Yellon
Journal:  Heart Fail Rev       Date:  2007-12       Impact factor: 4.214

View more
  35 in total

Review 1.  Cyclosporin variably and inconsistently reduces infarct size in experimental models of reperfused myocardial infarction: a systematic review and meta-analysis.

Authors:  W Y Lim; C M Messow; C Berry
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

Review 2.  Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection.

Authors:  Hans Erik Bøtker; Derek Hausenloy; Ioanna Andreadou; Salvatore Antonucci; Kerstin Boengler; Sean M Davidson; Soni Deshwal; Yvan Devaux; Fabio Di Lisa; Moises Di Sante; Panagiotis Efentakis; Saveria Femminò; David García-Dorado; Zoltán Giricz; Borja Ibanez; Efstathios Iliodromitis; Nina Kaludercic; Petra Kleinbongard; Markus Neuhäuser; Michel Ovize; Pasquale Pagliaro; Michael Rahbek-Schmidt; Marisol Ruiz-Meana; Klaus-Dieter Schlüter; Rainer Schulz; Andreas Skyschally; Catherine Wilder; Derek M Yellon; Peter Ferdinandy; Gerd Heusch
Journal:  Basic Res Cardiol       Date:  2018-08-17       Impact factor: 17.165

3.  Intralipid, a clinically safe compound, protects the heart against ischemia-reperfusion injury more efficiently than cyclosporine-A.

Authors:  Jingyuan Li; Andrea Iorga; Salil Sharma; Ji-Youn Youn; Rod Partow-Navid; Soban Umar; Hua Cai; Siamak Rahman; Mansoureh Eghbali
Journal:  Anesthesiology       Date:  2012-10       Impact factor: 7.892

4.  Disrupting the EMMPRIN (CD147)-cyclophilin A interaction reduces infarct size and preserves systolic function after myocardial ischemia and reperfusion.

Authors:  Peter Seizer; Carmen Ochmann; Tanja Schönberger; Sebastian Zach; Melanie Rose; Oliver Borst; Karin Klingel; Reinhard Kandolf; H Robson MacDonald; Romana A Nowak; Stefan Engelhardt; Florian Lang; Meinrad Gawaz; Andreas E May
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-03-24       Impact factor: 8.311

Review 5.  The coronary circulation in acute myocardial ischaemia/reperfusion injury: a target for cardioprotection.

Authors:  Derek J Hausenloy; William Chilian; Filippo Crea; Sean M Davidson; Peter Ferdinandy; David Garcia-Dorado; Niels van Royen; Rainer Schulz; Gerd Heusch
Journal:  Cardiovasc Res       Date:  2019-06-01       Impact factor: 10.787

6.  Reduction of early reperfusion injury with the mitochondria-targeting peptide bendavia.

Authors:  David A Brown; Sharon L Hale; Christopher P Baines; Carlos L del Rio; Robert L Hamlin; Yukie Yueyama; Anusak Kijtawornrat; Steve T Yeh; Chad R Frasier; Luke M Stewart; Fatiha Moukdar; Saame Raza Shaikh; Kelsey H Fisher-Wellman; P Darrell Neufer; Robert A Kloner
Journal:  J Cardiovasc Pharmacol Ther       Date:  2013-11-28       Impact factor: 2.457

7.  Cyclosporine A cardioprotection: mechanisms and potential for clinical application.

Authors:  Rolf Bünger; Robert T Mallet
Journal:  Crit Care Med       Date:  2013-04       Impact factor: 7.598

8.  Inhibition of permeability transition pore opening by mitochondrial STAT3 and its role in myocardial ischemia/reperfusion.

Authors:  Kerstin Boengler; Denise Hilfiker-Kleiner; Gerd Heusch; Rainer Schulz
Journal:  Basic Res Cardiol       Date:  2010-10-20       Impact factor: 17.165

9.  Targeted Modification of Mitochondrial ROS Production Converts High Glucose-Induced Cytotoxicity to Cytoprotection: Effects on Anesthetic Preconditioning.

Authors:  Filip Sedlic; Maria Y Muravyeva; Ana Sepac; Marija Sedlic; Anna Marie Williams; Meiying Yang; Xiaowen Bai; Zeljko J Bosnjak
Journal:  J Cell Physiol       Date:  2016-06-21       Impact factor: 6.384

Review 10.  Myocardial ischemia-reperfusion injury: a neglected therapeutic target.

Authors:  Derek J Hausenloy; Derek M Yellon
Journal:  J Clin Invest       Date:  2013-01-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.